Corion Biotech signed an agreement with “Officina Farmaceutica” University of Turin Cell factory (Italy) for GMP production of CB-ChMF-11 biological against preeclampsia. Corion Biotech signed an agreement with “Officina Farmaceutica” University of Turin Cell factory (Italy) for GMP production of CB-ChMF-11 biological against preeclampsia.amministratorecorion2021-09-07T11:59:15+02:001 July 2021|Read More
Corion Biotech S.r.l. receives European Medicines Agency (EMA) Orphan Drug Designation for Preeclampsia. Corion Biotech S.r.l. receives European Medicines Agency (EMA) Orphan Drug Designation for Preeclampsia.amministratorecorion2021-09-07T11:56:10+02:0012 May 2021|Read More
LIFTT and FINDE 1Mln round investment LIFTT and FINDE 1Mln round investmentamministratorecorion2021-09-07T12:01:36+02:0031 July 2020|Read More
Corion Biotech Granted Patent in Europe for the treatment of Epithelial Tumors by a Placental Mesenchymal Cells-derived biological. Corion Biotech Granted Patent in Europe for the treatment of Epithelial Tumors by a Placental Mesenchymal Cells-derived biological.amministratorecorion2021-09-07T11:29:08+02:0020 January 2018|Read More
corion biotech Granted Patent in Europe for the Treatment of Preeclampsia with a Placenta-derived biological. corion biotech Granted Patent in Europe for the Treatment of Preeclampsia with a Placenta-derived biological.amministratorecorion2021-09-07T11:22:24+02:0012 March 2016|Read More
